Skip to main content

Table 2 Pooled analysis of clinical characteristics of the 18 MuSK-MG patients

From: Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study

Variables

 Gender ratio, F:M

15:3

 Onset age (y), mean ± SD

40.28 ± 18.57

 Disease duration (m), median (IQR)

30.50 (17.50–44.75)

Onset symptoms

 Ocular, n (%)

11 (61.11)

 Bulbar, n (%)

10 (55.56)

 Limbs, n (%)

7 (38.89)

 Serum MuSK-ab titer (nmol/L) at diagnosis, mean ± SD

1.50 ± 2.80

RNS test positive

 Musculus deltoideus, n (%)

15 (83.33)

 Trapezius, n (%)

8 (44.44)

 Orbicular oculi, n (%)

12 (66.67)

 Abductor digiti minimi, n (%)

3 (16.67)

 Any muscles

15 (83.33)

Pyridostigmine test positive, n (%)

11 (61.11)

Thymic abnormalities on chest CT, n (%)

3 (16.67)

Symptoms involved over the disease course

 Ocular, n (%)

13 (72.22)

 Bulbar, n (%)

16 (88.89)

 Limbs, n (%)

7 (38.89)

 Myasthenic crisis, n (%)

5 (27.78)

QMGs before therapy, mean ± SD

12.83 ± 5.61

QMGs at last follow-up, mean ± SD

0.17 ± 0.51

  1. Abbreviations: QMGs Quantitative Myasthenia Gravis score, MuSK-ab Muscle-specific kinase antibody, RNS Repetitive nerve stimulation, CT Computed tomography, F Female, M Male, Y Year, m Month, n Number of patients, % Percentage, SD Standard deviation, IQR Interquartile range